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Abstract
Multiple sclerosis (MS) and functional neurological disorder (FND) are both diagnostically challenging conditions which 
can present with similar symptoms. We systematically reviewed the literature to identify patients with MS who were mis-
diagnosed with FND, patients with FND who were misdiagnosed with MS, and reports of patients with both conditions. In 
addition to FND, we included studies of patients with other functional and psychiatric disorders where these caused symptoms 
leading to investigation for or a diagnosis of MS, which in a different context would likely have been labeled as FND. Our 
review suggests that MS is one of the most common causes of misdiagnosis of FND and vice versa. We discuss the clinical 
errors that appear to result in misdiagnoses, such as over-reliance on psychiatric comorbidity when making a diagnosis of 
FND or over-reliance on neuroimaging for the diagnosis of MS, and practical ways to avoid them. Comorbidity between these 
two conditions is also likely common, has been poorly studied, and adds complexity to diagnosis and treatment in patients 
with both MS and FND. Misdiagnosis and comorbidity in a landscape of emerging evidence-based treatments for both MS 
and FND are issues not only of clinical importance to the care of these patients, but also to treatment trials, especially of 
MS, where FND could be a hidden confounder.
Keywords Multiple sclerosis · Functional neurological disorder · Conversion disorder · Psychogenic · Misdiagnosis
Introduction
Multiple sclerosis (MS) and functional neurological disor-
der (FND) are both diagnostically challenging conditions 
presenting at times with similarly disabling paroxysmal, 
fluctuating, and multifocal neurological symptoms. They 
also share a similar epidemiology, with a preponderance of 
female to male patients, and both are common conditions in 
neurological practice [1].
Misdiagnosis of MS or FND causes harm to patients, 
most generally in the form of a delay to diagnosis and ini-
tiation of proper treatment. Misdiagnosis of FND in patients 
who have MS may result in irreversible disability as a conse-
quence of delays in the initiation of disease modifying ther-
apy (DMT). However, DMTs carry unnecessary side-effects 
and risks for patients with FND who are misdiagnosed with 
MS. Patients with FND who are misdiagnosed with MS have 
a prognosis similar to MS [2] but which may improve with 
more modern evidence-based treatment [3]. Misdiagnosis 
can also cause psychological harm in patients if they par-
tially shape their identity around a diagnosis of MS or FND 
that they are later informed is incorrect [4, 5].
FND may also present as a comorbid condition in patients 
with an accurate diagnosis of MS, in which case both con-
ditions warrant treatment. Failure to detect comorbidity 
between FND and MS may result in unnecessary treatment 
of misdiagnosed relapses, and unwarranted escalation to 
higher risk DMTs in patients with MS, and could also pre-
sent an important confounder for MS research efforts that 
include assessment of clinical disability status.
In several previous studies, we noticed that when people 
who have MS are initially misdiagnosed, FND is often one 
of the conditions for which it is mistaken [6]; and when 
people with FND are misdiagnosed, often the erroneous 
diagnosis is MS [7]. Our findings prompted us to search the 
literature for further data concerning the diagnostic overlap 
between MS and FND.
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Our aim in this review is to summarize what is known 
about how often FND is misdiagnosed in patients with MS, 
how often MS is misdiagnosed in patients with FND, as 
well as comorbidity between these two disorders. We discuss 
potential sources of error in the diagnosis of each condition, 
and implications for both clinical care and future research.
Methods
We searched English-language studies on MEDLINE from 
1965 to April 2020 using the search:
("diagnostic error*" OR "misdiagnosis") AND ("multi-
ple sclerosis" OR ("functional neurological disorder*" 
OR "functional disorder*" OR "conversion disorder*" 
OR "somatization" OR "psychogenic" OR "dissocia-
tive" OR "hysteria"))
The abstracts of 512 papers yielded by this search were 
screened for relevance. We excluded case reports. We hand 
searched references of articles identified for additional 
studies relevant to this review. We included any study that 
focused on a diagnostic change between MS and FND, or 
their comorbidity. In addition to FND, we also included and 
reported studies reporting patients misdiagnosed as having 
another functional disorder (including fibromyalgia), a psy-
chiatric disorder, or “non-specific symptoms”. Patients are 
usually suspected of having MS because they have motor or 
sensory symptoms. We looked at a broader range of condi-
tions on the grounds that in many cases, it seems likely that 
clinicians may have made no diagnosis (e.g., non-specific 
symptoms) or focused on a comorbid disorder that they 
considered to be relevant or was perhaps dominant, such 
as anxiety or fibromyalgia, even though those diagnoses do 
not encompass the type of motor and sensory symptoms 
that typically lead to the evaluation for, or the diagnosis of, 
MS. For example, if a patient received a diagnosis of MS, 
but later was found not to have MS but in fact depression, it 
seems likely that in a different context, a diagnosis of FND 
would have been made, as depression could not have other-
wise caused neurological symptoms suggestive of MS.
Patients with multiple sclerosis who are 
misdiagnosed with functional neurological disorder
FND, also referred to as psychogenic, dissociative, and 
conversion disorder, consists of motor, sensory or seizure 
symptoms that can be identified as relating to a functional 
disorder. The core diagnostic feature in motor and sensory 
presentations is the finding of impairment in voluntary 
motor or sensory function which can be shown under other 
circumstances to be intact. A positive Hoover’s sign of leg 
weakness or positive tremor entrainment test are examples 
[1]. A number of studies, particularly if the numerous terms 
used to describe FND are considered, have found that MS 
may be misdiagnosed as FND (Table 1).
Patients with MS often experience a period of diagnos-
tic delay prior to receiving a diagnosis of MS [8]. The rea-
sons for this are multifactorial, and often involve systemic 
barriers to healthcare access. Although many studies have 
reported such diagnostic delay in MS care [8–12], only a few 
have documented specific misdiagnoses that were responsi-
ble for such delays (Table 1).
In a 1988 study, researchers identified all patients with 
a diagnosis of MS in prevalence assessments in 1976 and 
1981 in a region of New Zealand, and found that out of ten 
who had initially been seen by psychiatrists with symptoms 
attributable to MS, eight were diagnosed with a variety of 
psychiatric diagnoses for symptoms such as weakness, bal-
ance incoordination, sensory symptoms, and vision loss 
[13]. Four (50%) were given a diagnosis of “hysterical 
conversion” or similar. It is possible that these particular 
misdiagnoses might have been prevented using current MS 
diagnostic criteria that incorporate imaging techniques. 
However, similar findings were noted from an MS tertiary 
care center in Israel in 2003. 29 out of 50 (58%) consecu-
tive MS patients self-reported having initially been given 41 
different diagnoses prior to a diagnosis of MS; of those 29, 
9 (31%) were diagnosed with a psychiatric disorder includ-
ing anxiety, somatization, or conversion disorder (FND) 
[14]. In this study, eight additional patients reported that a 
physician had diagnosed them with “no problem” despite 
presenting with motor or sensory symptoms, and perhaps 
they would have been more explicitly diagnosed with FND 
by a different provider. In a 2019 study, 30 (23%) of 128 
patients with MS at five tertiary care centers in Portugal 
had received psychiatric diagnoses prior to a diagnosis of 
MS [15]. Similarly, in a 2020 study at a tertiary care center 
in Ukraine, 53 patients were initially misdiagnosed before 
receiving the correct diagnosis of MS, including one (2%) 
with generalized anxiety disorder and six (11%) with “other 
neuropsychiatric disorders” [16].
Further information about the misdiagnosis of MS as 
FND comes from cohort studies of FND (Table 1). A sys-
tematic review of diagnostic change in FND, incorporating 
27 studies and 1466 patients with a mean duration of 5 years 
going back to the 1950s, found that misdiagnoses of FND 
had been stable at approximately 4% since 1970. Revised 
diagnoses were reported in 68 out of 123 misdiagnosed 
patients; the most common were epilepsy (19%), multiple 
sclerosis (9%), and movement disorders (9%) [7]. In a subse-
quent prospective cohort study of patients referred to neurol-
ogy outpatient clinics in Scotland, only 4 (0.4%) out of 1030 
patients with FND acquired a subsequent unexpected new 
diagnosis which better explained the original symptoms, one 
of whom had MS [17]. In a 14-year prospective case–control 
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study of 89 patients with functional limb weakness pub-
lished in 2019, the only person who had a diagnosis at fol-
low-up which in hindsight may have been a better explana-
tion for their symptoms had been diagnosed with MS. This 
patient had comorbid FND and MS [18]. While these studies 
demonstrate low absolute numbers of patients with MS who 
were initially misdiagnosed as having FND, large cohort 
studies of FND focused on diagnosis are uncommon. Unlike 
MS cohort studies, these studies employed a restricted and 
more accurate definition of FND, whereas in the MS litera-
ture, functional disorders and psychiatric disorders are often 
grouped together with inconsistent terminology.
It is difficult to provide a reliable estimation of the fre-
quency of misdiagnosis of MS as FND owing to heteroge-
neity in design, outcome measures, diagnostic criteria, and 
terminology used. As a rough guide, from the FND cohort 
studies presented here, we would summarize that the overall 
misdiagnosis rate of FND is probably between 1 and 4% and 
that around 10% of these misdiagnoses may be MS related; 
in other words, around 0.1–0.4% of people with FND.
Patients with functional neurological disorder who 
are misdiagnosed with multiple sclerosis
Patients with functional and psychiatric disorders 
suspected of having MS
Studies reporting a diagnostic change in patients “suspected” 
of having MS are not clearly a misdiagnosis per se, since in 
many cases while MS is being entertained as a diagnosis, 
evaluation remains ongoing. However, if a sufficient number 
of patients referred for evaluation of suspected MS are found 
to have FND, it is reasonable to assume that some proportion 
of such patients are at risk for misdiagnosis of MS. Multiple 
studies spanning three decades reporting referral patterns to 
academic MS centers in several countries have consistently 
Table 1  Studies reporting patients with multiple sclerosis who were initially misdiagnosed with functional neurological disorder (FND), func-
tional disorder or psychiatric disorder
a This study only looked at diagnostic error in patients who had attended psychiatry clinics
Cohort studies of multiple sclerosis
Study Year data collected Methodology Misdiagnosed 
total






Skegg et al. [13] 1976 and 1981 Review of the psychiatry records of 91 patients with 
MS in New Zealand
8/91 (9%)a 8/8 (100%) 4/8 (50%)
Levin et al. [14] 2003 Survey of 50 patients with MS in Israel regarding 
misdiagnosis before confirmation of MS
29/50 (58%) 9/29 (31%) Not stated
Aires et al. [15] 2010–2015 Review of causes of diagnostic delay in 285 patients 
with MS in Portugal
128/285 
(45%)
30/128 (23%) Not stated
Ivaniuk et al. [16] 2007–2018 Review of records of 128 patients with MS in 
Ukraine for initial misdiagnosis
53/128 (41%) 7/53 (13%) Not stated
Cohort studies of functional neurological disorder









Stone et al. [7] 1949–2001 Systematic review of studies on diagnostic outcome of adults with a 





Stone et al. [17] 2002–2004 Prospective cohort study of patients with medically unexplained symp-
toms as rated by neurologist with 19-month follow-up
4/1030 (0.4%) 1/4 (25%)
Gelauff et al. [18] 2000–2003 Prospective cohort study of patients with functional limb weakness with 
14-year follow-up
1/89 (1%) 1/1 (100%)
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demonstrated that patients with FND are indeed frequently 
referred for evaluation for a diagnosis of MS (Table 2).
In a study of 400 consecutive patients referred to a ter-
tiary MS research unit between 1979 and 1983 (and thus 
predating the common use of MRI in MS diagnosis) in Can-
ada, 14 out of 52 (27%) patients who did not have MS had 
psychiatric conditions, including two with “hysteria” [19]. 
In a retrospective review of 281 new patient evaluations at 
a tertiary MS center in the United States between 2001 and 
2003, 63 out of 186 (34%) patients who did not have MS 
or possible MS had “possible psychiatric disease” [20]. 
These patients with psychiatric diagnoses had one or more 
of “somatoform disorders” (76%), mood disorders (33%), 
and/or anxiety disorders (11%) [21]. Conversely, there were 
no diagnoses of FND or psychiatric disorders in a Dutch 
retrospective review from 1998 to 2001, where 116 out of 
377 (31%) consecutive patients referred for a second opin-
ion to a tertiary MS center had diagnoses other than MS or 
demyelinating disease [22]. Of these patients, 29 (25%) had 
another neurological disease, none of whom had FND or 
psychiatric disorders (although five “single diagnoses” were 
not specified). This study is particularly limited because in a 
significant proportion of patients, including 80% at follow-
up 7 years later, no diagnosis could be identified [23].
In an American tertiary MS center from 2004 to 2007, the 
most common diagnosis was “psychiatric disease” in 53 out 
of 70 (76%) patients who had been referred for MS evalu-
ation but did not have MS [24]. A retrospective review of 
all patients presenting to a Brazilian demyelinating disease 
center from 1994 to 2013 found that 495 out of 1599 (31%) 
did not have MS, of whom 108 (22%) had “other diagnosis”, 
which included psychiatric disorders, although the propor-
tion was not specified [25]. In Lebanon and Kuwait between 
2011 and 2015, the most common alternative diagnosis in 
131 patients referred with clinical or radiological suspicion 
of MS to two tertiary MS centers for diagnostic confirmation 
of MS, who did not have a confirmed diagnosis of MS, was 
“psychogenic” in 19 (16%) [26].
A study across 22 MS centers in Italy published in 2019 
included 667 patients who were referred for suspected MS 
and followed up for up to three years if their diagnosis 
remained uncertain. Of 163 patients who did not have MS 
or clinically isolated syndrome, nine (6%) had psychiatric 
or functional diagnoses: five had “psychiatric disorder” and 
four had fibromyalgia [27]. Notably, this study also high-
lighted a large number of patients with “nonspecific neuro-
logic symptoms” associated “with atypical MRI” (n = 10) 
and “with atypical MRI lesions of suspected vascular origin” 
(n = 40). These are likely to represent a heterogenous group 
so we have not included them in Table 2, although at least 
some may have attracted a diagnosis of a functional disorder 
in other settings. Lastly, in a recent prospective pilot study 
evaluating an emerging MRI diagnostic biomarker for MS 
(“central vein sign”) in patients with diagnostic uncertainty, 
three out of 23 (13%) patients who did not have MS had 
FND or functional sensory symptoms [28].
Table 2  Studies reporting final diagnoses in patients referred for evaluation to tertiary MS centers
Study Year data collected Centre where evaluation 
of MS took place
Patients with diagnoses 
other than MS
Proportion of diagnoses other than 
MS which were FND, functional 
disorder or psychiatric diagnoses
Murray and Murray [19] 1979–1983 Tertiary center, Canada 52/400 (13%) “Psychiatric conditions”: 14/52 (27%) 
[anxiety (n = 6), depression (n = 4), 
hysteria (n = 2)]
Nielsen et al. [22, 23] 1998–2001 Tertiary center, Neth-
erlands
116/377 (31%) No diagnoses of FND or psychiatric 
disorders
“No certain diagnosis could be 
made”: 87/116
Carmosino et al. [20], 
Brousseau et al. [21]
2001–2003 Tertiary center, United 
States
186/281 (66%) “Possible psychiatric”: 63/186 (34%) 
[somatoform (n = 48), mood disor-
ders (n = 21), anxiety (n = 7)]
Rolak and Fleming [24] 2004–2007 Tertiary center, United 
States
70/142 (49%) “Psychiatric”: 53/70 (76%)
Bichuetti et al. [25] 1994–2013 Tertiary center, Brazil 495/1599 (31%) Not specified
“Other diagnosis” 108/495
Yamout et al. [26] 2011–2016 Tertiary centers, Leba-
non and Kuwait
131/431 (30%) “Psychogenic”: 19/131 (15%)
Calabrese et al. [27] 2014 22 tertiary centers, Italy 163/667 (24%) Total: 9/163 (6%) [“psychiatric” 
(n = 5), “fibromyalgia” (n = 4)]
Clarke et al. [28] 2015–2018 Tertiary center, United 
Kingdom
23/35 (66%) FND or functional sensory symptoms: 
3/23 (13%)
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In summary, at tertiary MS centers across a wide geo-
graphic distribution and over a long duration of time 
encompassing numerous revisions to MS diagnostic cri-
teria, patients who ultimately had psychiatric disorder, or 
functional disorder including FND, have been consistently 
referred for evaluation for a diagnosis of MS. The frequency 
of such referrals of patients with FND for MS diagnostic 
evaluations raises the chance of MS misdiagnoses in these 
patients.
Patients with functional neurological disorder 
misdiagnosed as having multiple sclerosis
In a 2012 survey of 122 MS specialists, 95% reported that 
they had evaluated in the last year at least one patient who 
they strongly felt did not have MS despite having carried 
a diagnosis of MS for at least a year [29]. Many had seen 
numerous such patients over the preceding year. When asked 
to recall alternate diagnoses in such misdiagnosed patients, 
the fourth most common disorder reported was psychiatric 
disorder (45%) and the sixth was fibromyalgia (31%).
Several studies of varying size and methodological 
approaches have described characteristics of patients mis-
diagnosed with MS, including numerous patients with final 
correct diagnoses of functional and psychiatric disorders 
(Table 3).
In a 1981 study including 69 patients misdiagnosed with 
MS, 35 (51%) had a functional or psychiatric diagnosis: 16 
had a functional disorder, 14 had anxiety/hyperventilation, 
three had “hysterical conversion”, and two had depression 
[30]. A 1986 case series describing ten patients who were 
misdiagnosed with MS found one patient whose final diag-
nosis was “hysteria” [31]. A 1997 study of 366 patients with 
a diagnosis of MS referred for a second opinion to Charles 
Poser found 130 misdiagnosed patients, including 28 (22%) 
with chronic fatigue syndrome and eight (6%) with “psy-
chiatric disorder” or “post-traumatic syndrome” [32]. Of 
note, these studies predate the incorporation of MRI into 
MS diagnostic criteria in 2001 and may be less representa-
tive of contemporary misdiagnosis.
Table 3  Studies reporting patients with functional or psychiatric disorder misdiagnosed as MS
Study Year data collected Methodology Total misdiagnosed Proportion misdiagnosed with FND, 




1981 Reviewed records of 
patients either diagnosed 
with or told they might 
have MS
69/387 (17%) All categories: 35/69 (51%)
Functional disorder (n = 16), anxiety/
hyperventilation (n = 14), hysteri-
cal conversion (n = 3), depression 
(n = 2)
Rudick et al. [31] 1986 Case series of ten patients 
who were misdiagnosed 
with MS
10 (n/a) “Hysteria”: 1/10 (10%)
Poser [32] 1997 Review of patients with 
MS diagnosis referred 
for second opinion
130/366 (36%) All categories: 36/130 (28%)
Chronic fatigue syndrome (n = 28), 
post-traumatic syndrome (n = 5), 
psychiatric disorders (n = 3)
Walzl et al. [34] 2002–2004 Prospective cohort study 
of new neurology out-
patients including 209 
with MS
9/209 (4%) All categories: 3/9 (33%)
Anxiety (n = 2), chronic fatigue syn-
drome (n = 1)
Solomon et al. [6] 2014–2015 Multicenter case series 
comprised of patients 
misdiagnosed with MS
110 (n/a) All categories: 28/110 (25%)
Fibromyalgia (n = 16), conversion or 
psychogenic disorder (n = 12)
De Seabra et al. [36] 2009–2016 Retrospective study 
reviewing patient 
records at an MS clinic 
between 2009 and 
2016 by applying 2010 
McDonald criteria
44/635 (7%) All Categories: 2/44 (5%)
Dissociative disorder (n = 1), fibromy-
algia (n = 1)
Kaisey et al. [35] 2016–2017 Patients with a prior 
established diagnosis 
of MS were reviewed 
in clinic and evaluated 
for fulfilment of 2010 
McDonald criteria
43/241 (18%) Fibromyalgia: 2/43 (5%)
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In the Scottish Neurological Symptoms Study (SNSS), 9 
out of 209 (4%) patients with a diagnosis of MS or demy-
elination [33] at baseline had an alternative diagnosis at 
18 months follow-up, of whom three (33%) had a functional 
disorder or psychiatric diagnosis at follow-up (anxiety and 
chronic fatigue syndrome) [34]. In a 2016 multicenter case 
series reporting 110 patients misdiagnosed with MS, 12 
(11%) had “conversion or psychogenic disorder”, the fourth 
most common diagnosis. Also of note, 16 (15%) were diag-
nosed with fibromyalgia, and 13 (12%) with non-specific 
or non-localizing neurologic symptoms with abnormal 
MRI [6]. In contrast, in a 2019 study in California, there 
were no cases of FND among 43 misdiagnosed MS patients 
referred to two MS tertiary care centers, although there 
were two cases (5%) of fibromyalgia [35]. An additional 
recent study in 2020 in Portugal reported 44 misdiagno-
ses in 635 patients (7%) referred to an MS clinic between 
2009 and 2016 [36]. Of those, one had dissociative disorder 
and another fibromyalgia, and nine had non-specific MRI 
changes with unclear explanations for their symptoms.
Once again, it is hard to distill the data to a ‘headline figure’, 
but it can be seen that the frequency of MS misdiagnosis for all 
conditions ranged from 4 to 36%. The differential diagnosis of 
MS is broad, but within this misdiagnosed group, functional 
or psychiatric disorders were consistently seen, making up 
between 5 and 51% of patients with these diagnostic errors. 
The estimates therefore seem somewhat higher in this direction 
than for patients erroneously misdiagnosed as FND.
Sources of clinical error in misdiagnosis
The literature reviewed above supports that the misdiagnosis 
of FND as MS, and vice versa, is not infrequent. Both FND 
and MS can result in disabling paroxysmal or fluctuating 
neurological symptoms in young adults, and accurate diag-
nosis in both disorders relies on a skilled clinical assessment. 
There remains no highly specific biomarker for either MS 
or FND. However, consensus clinical criteria for MS have 
performed with high accuracy when used correctly [37]. 
Diagnostic criteria for FND based on DSM-5 emphasize 
finding evidence of clinical incompatibility with recognized 
diseases, which in practice requires the presence of positive 
signs of internal inconsistency and incongruity [1]. Clinical 
practice suggests that FND diagnoses do generally remain 
stable [7, 17, 18], but more work needs to be done to define 
the disorder and its many symptoms and subtypes.
Clinician reliance on a history of psychiatric comorbidity 
or of adverse experience is one of the most common reasons 
for an incorrect diagnosis of FND [38]. Such factors may 
be important in formulation or treatment when present, but 
are so common that they are not of diagnostic value. Addi-
tionally, failing to adequately rely on clear positive clini-
cal examination signs of FND to make the diagnosis [1], or 
placing weight on a “bizarre” presentation which the clini-
cian finds hard to explain [38] are common errors from our 
experience. Conversely, patients who are older, male and do 
not conform to stereotypes about FND may experience over-
diagnosis with disease diagnoses such as MS.
Data from studies focused on MS [6, 35] suggest that mis-
application and misinterpretation of MS diagnostic criteria 
may be responsible for many cases of misdiagnosis. The 
McDonald criteria require successive clinical assessments. 
In cases of FND misdiagnosed as MS, it is likely that the 
McDonald criteria are applied in patients presenting without 
one of the required “typical syndromes” for MS, “objec-
tive evidence” on neurological examination or paraclinical 
testing of a corroborating central nervous system lesion. 
Instead, an over-reliance on brain MRI imaging abnormal-
ities that can be attributed to a variety of other common 
causes (including small vessel ischemic disease, migraine, or 
healthy aging) that fulfill the MRI portion of the McDonald 
criteria, accompanied by non-specific or non-CNS local-
izing neurological symptoms, may often fit the profile of 
patients with FND misdiagnosed with MS. Conversely, the 
widespread adoption of MRI for the diagnosis of MS that 
has occurred since the completion of a number of the above 
studies may have resulted in fewer patients with MS having 
been misdiagnosed with FND.
Neither MS nor FND should be approached as a diagno-
sis of exclusion. The clinical assessments required to fulfill 
the McDonald criteria, and specific examination findings in 
FND (i.e., positive signs) increase specificity for a diagno-
sis of each disorder. Diagnosing MS in patients with MRI 
abnormalities and with no better explanation for their neuro-
logical symptoms increases the risk of misdiagnosis. Simi-
larly, making a diagnosis of FND in a patient with a normal 
MRI and unexplained non-specific neurological symptoms 
is incorrect and likely to lead to misdiagnosis.
Comorbidity of functional neurological disorder 
and multiple sclerosis
Is a diagnosis of FND in a patient with MS always an error? 
Most neurologists specializing in MS recognize that they 
commonly see patients who clearly have an accurate diag-
nosis of MS, yet also have symptoms and/or signs which 
suggest that they have a comorbid functional disorder. This 
kind of FND comorbidity is well recognized for other neu-
rological conditions. For example, up to 20% of patients 
with dissociative non-epileptic seizures have a history of, or 
comorbid, epilepsy [39], and studies of Parkinson’s disease 
are increasingly highlighting FND as a comorbidity, espe-
cially in the prodromal period [40].
Neurologists as far back as Charcot recognized that patients 
with MS and functional disorders could be intertwined. 
Gowers wrote that “hysterical and emotional disturbance are 
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common (in MS), even in men” [41]; Oppenheim wrote that 
“Multiple sclerosis is frequently associated with hysteria” 
[42]; and Russell Brain wrote in 1930 that “Hysterical symp-
toms, such as pareses and ataxia, seem to occur more often in 
association with disseminated sclerosis than with any other 
organic disease of the nervous system” [43]. Wilson, on the 
other hand, viewed “hysteria” and multiple sclerosis as sepa-
rate, and although he recognized that “hysteria” was common, 
when diagnosed in the early stages, or “pre-disseminated” 
form of MS, he thought it represented a misdiagnosis [44].
Although widely acknowledged, there is scant data on 
the prevalence of FND comorbidity with MS [45, 46]. In 
a study of 366 patients with MS in Denmark in the 1970s 
and 80s, five (1%) had psychiatric admissions for “hysteric” 
neuroses in relation to and after the onset of MS [47]. A case 
series of four similar patients with both MS and “hysteria” 
was published in JAMA in 1980 [48]. In a 2011 study of 
new neurology outpatients with a diagnosis of neurological 
disease, 32 out of 252 (13%) patients with MS were rated 
by the neurologist as having symptoms only “somewhat” or 
“not at all” explained by that disease [33]. One unpublished 
conference abstract from 2019 reported that 7.5% of 120 
German MS patients had “inconsistent findings that could 
not be explained neurologically” [49].
Studies of MS “pseudorelapses” in children [50] and 
adults [51, 52] have highlighted that FND can be a potential 
cause of an apparent MS relapse. Although relapse was not 
specified as a reason for the visits, “non-organic” presenta-
tions accounted for 12 out of 371 (3%) rapid access visits to 
an MS service in Wales, UK [52].
The comorbidity of MS with psychiatric diagnoses has 
been more extensively studied. A comprehensive system-
atic review of 118 studies on psychiatric comorbidities in 
MS found that psychiatric comorbidities were common; in 
particular, the prevalence of diagnosed anxiety and depres-
sion were estimated at 21.9 and 23.7%, respectively [53]. A 
study of comorbidity in patients with MS found that the 668 
patients who also self-reported mental comorbidities expe-
rienced a delay to diagnosis of MS, and were more likely 
to have severe, rather than mild, disability two years after 
diagnosis [54]. A nationwide cohort study in Denmark did 
not find a statistically significant increase in diagnostic delay 
in patients with psychiatric comorbidity, perhaps due to a 
small number of patients (n = 75), but there was a signifi-
cantly increased mortality [55]. It is important to understand 
that FND and functional disorders are not synonyms for 
psychiatric disorder; they are conditions in their own right 
that do occur without psychiatric comorbidity. Nonetheless, 
FND and functional disorders also are known for a high fre-
quency of psychiatric comorbidity as well as disturbances in 
emotional regulation that have also been found in MS [56]. 
Therefore, the presence of depression or anxiety could add 
to both the misdiagnosis of FND and MS.
In conclusion, the topic of FND and MS comorbidity 
is poorly researched, but the studies we have do suggest it 
occurs, and following a renaissance in FND diagnosis and 
evidence-based treatment, is now worthy of more careful 
study.
Clinical care and research
What are the consequences of misdiagnosing FND in a 
patient with MS? Difficulties will be especially magnified 
if the neurologist making the original FND diagnosis did 
so in a way that failed to validate the patient’s symptoms 
or provide onward treatment. Whereas in the past, missing 
a diagnosis of MS could have been said not to have led to a 
change in prognosis, that is no longer the case with newer 
disease modifying agents [57].
The implications of misdiagnosis of MS in patients who 
have FNDs include unnecessary treatment of MS and its 
accompanying side-effects and risks, delay to diagnosis and 
treatment of FND, and psychological harm as a result of 
misdiagnosis. In one study, 31% of patients misdiagnosed 
with MS experienced unnecessary morbidity as a result of 
misdiagnosis, most commonly due to unnecessary immu-
nomodulatory therapy and treatment side-effects [6]. Tradi-
tionally, neurologists may have considered that accidentally 
diagnosing MS in someone with FND was less harmful 
because of a lack of established treatment options for FND. 
However, the scientific landscape around FND has changed 
considerably in the last 10 years [1]. Patients with FND 
erroneously diagnosed with MS miss out on increasingly 
evidence-based treatment for their functional symptoms. For 
example, a randomized controlled trial of specialized physi-
otherapy for functional motor symptoms found that 72% of 
patient had improvements in mobility sustained at 6 month 
follow-up compared to 18% in a control arm having non-
specialized physiotherapy [3].
The diagnosis of a neurodegenerative disease such as 
MS can have a life-altering psychological effect on patients. 
Patients can shape their identity around their diagnosis, and 
it is difficult for neurologists to remove a diagnosis of MS 
without concern of causing yet more harm to the patient [4, 
5]. This is perhaps especially the case when the new diag-
nosis is one of a functional disorder, when the neurologist 
may feel less equipped to help than they were with an MS 
diagnosis [58].
Identifying comorbid FND and MS can lead to funda-
mental differences in treatment. The treatment of FND 
depends firstly on establishing with the patient that they 
have a condition which is potentially reversible, and related 
to a problem in the “software” of the nervous system, rather 
than a “hardware” problem as seen in established MS. Sec-
ond, the type of physical rehabilitation that has been devel-
oped for FND uses a transparent explanatory model for the 
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disorder which takes advantage of the inconsistencies seen 
on examination and turns them into therapeutic opportu-
nities during therapy [3]. So, a patient with FND may be 
discouraged from thinking too hard about their walking and 
to actively use distraction techniques to improve function, 
whereas in therapy for someone with MS, the patient may be 
asked to concentrate hard on the affected limb. Furthermore, 
recognition of FND comorbidity in patients with MS has 
important consequences for the assessment of MS relapses. 
In such patients, additional paraclinical testing, such as MRI, 
might be necessary to confirm “objective evidence” of a 
CNS lesion responsible for symptoms or challenging neu-
rological exam findings.
Lastly, the identification of patients with MS and FND 
comorbidity may have a further benefit for MS research. 
Patients with FND comorbidity may increase “signal to 
noise ratio” in clinical trials of new therapies for MS with 
subjectively rated clinical outcome measures. If reliable 
ways could be found to exclude such patients, this could 
lead to better data from trials of MS therapeutic agents, a 
concept that has also been proposed in relation to functional 
cognitive disorders and dementia trials [59].
Conclusions
MS and FND are common conditions that are not infre-
quently mistaken for one another, and which may co-exist 
more often than is currently acknowledged. Improved clini-
cal recognition and broader research efforts focused on the 
overlap of these two disabling disorders has potentially 
important consequences for the care of patients with MS 
and FND and for treatment studies in both conditions.
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